Peripheral antinociceptive effect of 2-arachidonoyl-glycerol and its interaction with endomorphin-1 in arthritic rat ankle joints

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 5-6, 2010, Pages 544-550

  Mecs, Laszlo ^b   Tuboly, Gabor ^a   Toth, Kalman ^b   Nagy, Endre ^b   Nyari, Tibor ^c   Benedek, Gyorgy ^a   Horvath, Gyöngyi ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antinociceptive activity; Arthritis; Cannabinoid; Inflammation; Interaction; Opioid; Pain; Peripheral sensory neurons

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; CANNABINOID RECEPTOR; CARRAGEENAN; ENDOMORPHIN 1; NALTREXONE; OPIATE RECEPTOR; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AFFECTING AGENT; ENDOCANNABINOID; LIGAND; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE EDEMA; ANTINOCICEPTION; ARTHRALGIA; ARTHRITIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; MALE; MECHANICAL STIMULATION; MONOTHERAPY; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NERVE; RAT; ANIMAL; ARTHRITIS, EXPERIMENTAL; DRUG EFFECTS; EDEMA; METABOLISM; TARSAL JOINT; WISTAR RAT;

ANALGESICS, OPIOID; ANIMALS; ARACHIDONIC ACIDS; ARTHRITIS, EXPERIMENTAL; CANNABINOID RECEPTOR MODULATORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EDEMA; ENDOCANNABINOIDS; GLYCERIDES; LIGANDS; MALE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; PAIN THRESHOLD; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; TARSAL JOINTS;

EID: 77951096727     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05346.x     Document Type: Article

References (56)

1. Fields HL, Emson PC, Leigh BK, Gilbert RFT, Iversen LL. Multiple opiate receptor sites on primary afferent fibers. Nature 1980 284 : 351 353.
2. Stein C. Peripheral mechanisms of opioid analgesia. Anesth. Analg. 1993 76 : 182 191.
3. Stein C, Hassan AHS, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effects of endogenous opioid peptides. Lancet 1993 342 : 321 324.
4. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997 386 : 499 502.
5. Horvath G. Endomorphin-1 and endomorphin-2. Pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacol. Ther. 2000 88 : 437 463.
6. Obara I, Przewlocki R, Przewlocka B. Local peripheral effects of mu-opioid receptor agonists in neuropathic pain in rats. Neurosci. Lett. 2004 360 : 85 9.
7. Labuz D, Berger S, Mousa SA et al. Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. J. Neurosci. 2006 26 : 4350 4358.
8. Mecs L, Tuboly G, Nagy E, Benedek G, Horvath G. Peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint model. Anesth. Analg. 2009 109 : 1297 1304.
9. Straub RH, Wolff C, Fassold A et al. Antiinflammatory role of endomorphins in osteoarthritis, rheumatoid arthritis, and adjuvant-induced polyarthritis. Arthritis Rheum. 2008 58 : 456 466.
10. Li ZM, Proud D, Zhang CF, Wiehler S, McDougall JJ. Chronic arthritis down-regulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin 1 antinociception. Arthritis Rheum. 2005 52 : 3210 3219.
11. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 2001 63 : 569 611.
12. Agarwal N, Pacher P, Tegeder I et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007 10 : 870 879.
13. Lever IJ, Rice ASC. Cannabinoids and pain. Handb. Exp. Pharmacol. 2007 177 : 265 306.
14. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002 121 : 173 190.
15. Jhaveri MD, Sagar DR, Elmes SJR, Kendall DA, Chapman V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol. Neurobiol. 2007 36 : 26 35.
16. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 2003 17 : 2750 2754.
17. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008 108 : 722 734.
18. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 258 : 1946 1949.
19. Mechoulam R, Ben Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995 50 : 83 90.
20. Desroches J, Guindon J, Lambert C, Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br. J. Pharmacol. 2008 155 : 913 924.
21. Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br. J. Pharmacol. 2007 150 : 693 701. (Pubitemid 46440208)
22. Horvath G, Kekesi G. Interaction of endogenous ligands mediating antinociception. Brain Res. Rev. 2006 52 : 69 92.
23. Kolesnikov Y, Soritsa D. Analgesic synergy between topical opioids and topical non-steroidal anti-inflammatory drugs in the mouse model of thermal pain. Eur. J. Pharmacol. 2008 579 : 126 133.
24. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 1992 262 : 10 18.
25. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 1999 20 : 287 294.
26. Tuboly G, Mecs L, Benedek G, Horvath G. Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Clin. Exp. Pharmacol. Physiol. 2009 36 : 400 405.
27. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004 74 : 1317 1324.
28. Radhakrishnan R, Moore SA, Sluka KA. Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain 2003 104 : 567 577.
29. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990 300 : 230 235. (Pubitemid 20045528)
30. Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 1989 45 : 947 961.
31. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 1999 848 : 183 190.
32. Maldonado R, Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur. Neuropsychopharmacol. 2003 13 : 401 410.
33. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 2007 153 : 319 334.
34. Griffin G, Fernando SR, Ross RA et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 1997 339 : 53 61.
35. Nackley AG, Suplita RL II., Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003 117 : 659 670.
36. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998 75 : 111 119.
37. Guindon J, De Lean A, Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 2006 121 : 85 93.
38. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998 394 : 277 281.
39. Richardson D, Pearson RG, Kurian N et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 2008 10 : R43 (doi :).
40. Schuelert N, McDougall JJ. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008 58 : 145 153.
41. Gauldie SD, McQueen DS, Pertwee R, Chessell IP. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 2001 132 : 617 621.
42. Lam FFY, Luk PWS, Ng ESK. Pharmacological characterization of receptor types mediating the dilator action of anandamide on blood vessels of the rat knee joint. Life Sci. 2007 80 : 1495 1502.
43. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 2007 114 : 13 33.
44. 2+-dependent and -independent mechanisms. FEBS Lett. 1998 429 : 152 156.
45. Bisogno T. Endogenous cannabinoids: structure and metabolism. J. Neuroendocrinol. 2008 20 : 1 9.
46. Mechoulam R, Ben Shabat S, Hanus L et al. Endogenous Cannabinoid Ligands. AIDS, Drugs of Abuse, and the Neuroimmune Axis. Plenum Press
47. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 2000 275 : 33744 33749.
48. Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 2008 283 : 22601 22611.
49. Ben Shabat S, Fride E, Sheskin T et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 1998 353 : 23 31.
50. Jessop DS, Richards LJ, Harbuz MS. Opioid peptides endomorphin-1 and endomorphin-2 in the immune system in humans and in a rodent model of inflammantion. Ann. NY Acad. Sci. 2002 966 : 456 463.
51. McDougall JJ, Barin AK, McDougall CM. Loss of vasomotor responsiveness to the mu-opioid receptor ligand endomorphin-1 in adjuvant monoarthritic rat knee joints. Am. J. Physiol. 2004 286 : R634 41.
52. 9-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 2003 304 : 1010 1015.
53. Yesilyurt O, Dogrul A, Gul H et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003 105 : 303 308.
54. Yesilyurt O, Dogrul A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. Neurosci. Lett. 2004 371 : 122 127.
55. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000 100 : 685 688.
56. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complex. Neuropsychopharmacology 2000 23 : S5 18.